<DOC>
	<DOCNO>NCT03084237</DOCNO>
	<brief_summary>This Phase III , double-blind , randomize multicenter study compare efficacy evaluate safety immunogenicity HLX02 European Union ( EU ) -sourced Herceptin® patient human epidermal growth factor receptor 2 ( HER2 ) -positive , locally recurrent previously untreated metastatic breast cancer .</brief_summary>
	<brief_title>Clinical Study Compare Efficacy Evaluate Safety Immunogenicity Trastuzumab Biosimilar HLX02 EU-sourced Herceptin® HER2-Positive , Locally Recurrent Previously Untreated Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Female ≥18 year age day sign informed consent form ( ICF ) Histologically cytologically confirm adenocarcinoma breast Locally recurrent disease amenable curative surgery radiation therapy , metastatic disease indication taxanecontaining therapy Availability formalinfixed paraffinembedded tissue block primary tumor , metastatic lesion , confirm HER2positivity central laboratory , base FISH amplification ratio ≥2.0 IHC score 3+ , hormone status ( ER/PgR ) determination ( local central laboratory ) . If possible , fresh biopsy require No prior systemic chemotherapy , biological target agent recurrent metastatic disease . Prior neo/adjuvant hormone therapy must stop least 4 week randomization . Use herbal remedy traditional Chinese medicine anticancer , hematologic liver function , antiinfective treatment must stop least 2 week randomization time ICF signature late Prior neo/adjuvant therapy contain trastuzumab and/or lapatinib ( exclude HER2targeting agent ) must stop least 12 month ICF signature . If trastuzumab use , prior neo/adjuvant therapy taxane must stop least 6 month ICF signature . Prior neo/adjuvant therapy cytotoxics and/or hormone therapy must stop least 4 week ICF signature Measurable disease ( least one measurable target lesion assess CIR ; boneonly central nervous system [ CNS ] metastases allow ) Eastern Cooperative Oncology Group performance status 01 Left ventricular ejection fraction ( LVEF ) within institutional range normal baseline ( within 42 day randomization ) determine either echocardiography ( ECHO ) multigated acquisition ( MUGA ) scan Adequate hematologic , hepatic renal function Estimated life expectancy ≥3 month Female patient eligible enter participate study : Nonchildbearing potential Childbearing potential , negative serum pregnancy test Screening ( within 7 day first investigational product administration ) , breast feeding , use highlyeffective contraceptive measure study entry throughout study 6 month last investigational product administration . Previously currentlytreated ( systemic chemotherapy , biological , targeted agent , anticancer agent ) recurrent metastatic breast cancer Known brain metastasis CNS metastasis either symptomatic untreated . Central nervous system metastasis treat complete resection and/or radiotherapy demonstrate stability improvement exclusion criterion provide stable show computed tomography ( CT ) scan least 4 week Screening without evidence cerebral edema requirement corticosteroids anticonvulsant Underlying medical condition current severe , uncontrolled systemic disease , Investigator 's opinion , make administration study drug hazardous . A major surgical procedure ( defined procedure would require 3 week without study treatment ) within 4 week prior enrolment anticipation need major surgery course study Current uncontrolled hypertension ( systolic &gt; 150 mmHg and/or diastolic &gt; 100 mmHg ) unstable angina . History chronic heart failure New York Heart Association criterion , serious cardiac arrhythmia require treatment ( except atrial fibrillation , paroxysmal supraventricular tachycardia ) . History myocardial infarction within 6 month randomization . History LVEF decline 50 % prior trastuzumab neoadjuvant adjuvant therapy History prior exposure doxorubicin &gt; 360 mg/m² ( equivalent ) Use oral , injected implant hormonal method contraception Known hypersensitivity study drug Residual nonhematologic toxicity ≥ Grade 2 prior therapy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>